Bausch + Lomb BLCO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Pharmaceuticals | $1.13B+4.1% | $1.08B+5.0% | $1.03B+3.3% | $997M+1.5% | $982M+1.3% | |
| Surgical | $908M+1.6% | $894M+2.1% | $876M+1.0% | $867M+0.8% | $860M+2.0% | |
| Vision Care | $2.98B+1.9% | $2.92B+1.9% | $2.87B+1.8% | $2.82B+2.0% | $2.76B+0.8% | |
| Operating Income (Loss) by Business | ||||||
| Pharmaceuticals | $313M+21.3% | $258M+43.3% | $180M+4.0% | $173M-19.2% | $214M-16.4% | |
| Surgical | $34M+88.9% | $18M-5.3% | $19M-20.8% | $24M-7.7% | $26M-40.9% | |
| Vision Care | $875M+3.1% | $849M+1.2% | $839M+1.9% | $823M+2.1% | $806M-0.2% | |
| Selling, general and administrative (Note 4) by Business | ||||||
| Pharmaceuticals | $557M-2.6% | $572M-4.2% | $597M-0.8% | $602M+4.9% | $574M+5.7% | |
| Surgical | $298M0.0% | $298M+3.5% | $288M+2.9% | $280M+2.2% | $274M+3.4% | |
| Vision Care | $919M+0.8% | $912M+1.7% | $897M+0.7% | $891M+0.8% | $884M+0.2% | |
| R&D by Business | ||||||
| Pharmaceuticals | $66M+24.5% | $53M+12.8% | $47M+20.5% | $39M+8.3% | $36M+9.1% | |
| Surgical | $45M+4.7% | $43M-8.5% | $47M+2.2% | $46M+4.5% | $44M+4.8% | |
| Vision Care | $50M+4.2% | $48M+9.1% | $44M+7.3% | $41M0.0% | $41M-10.9% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Pharmaceuticals | -$59M+43.8% | -$105M-119% | -$48M+38.5% | -$78M-3,800% | -$2M-104% | |
| Surgical | -$5M+61.5% | -$13M-160% | -$5M+44.4% | -$9M-350% | -$2M-140% | |
| Goodwill by Business | ||||||
| Pharmaceuticals | $2.97B+1.9% | $2.91B+3.6% | $2.81B+1.6% | $2.77B+2.9% | $2.69B+0.1% | |
| Surgical | $1.64B+6.6% | $1.54B+7.6% | $1.43B+2.2% | $1.4B+2.8% | $1.36B+2.3% | |
| Vision Care | $14.22B+0.1% | $14.2B+0.2% | $14.17B0.0% | $14.17B+0.1% | $14.16B-0.1% | |
| Total revenues by Product | ||||||
| Branded and Other Generics | $237M-2.1% | $242M+0.8% | $240M-4.4% | $251M-6.7% | $269M-4.3% | |
| Devices | $1.95B+1.7% | $1.92B+2.2% | $1.88B+1.6% | $1.85B+1.5% | $1.82B+1.3% | |
| OTC | $1.87B+1.9% | $1.84B+1.5% | $1.81B+1.9% | $1.77B+2.0% | $1.74B+0.8% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $5M0.0% | $5M-16.7% | $6M+20.0% | $5M+25.0% | $4M0.0% | |
| Product sales | $2.05B0.0% | $2.05B+1.6% | $2.01B+2.3% | $1.97B+2.1% | $1.93B+3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch + Lomb break its business down?
- Bausch + Lomb (BLCO) reports total revenues by business across 3 parts — Pharmaceuticals, Surgical and Vision Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch + Lomb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch + Lomb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.